NCT04446026View on ClinicalTrials.gov

A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

December 7, 2020

Study Completion Date

May 17, 2021

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

teneligliptin

teneligliptin 20mg PO qd for 24weeks

DRUG

Placebo

teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks

Trial Locations (1)

Unknown

Yonsei Severance Hospital, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT04446026 - A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen | Biotech Hunter | Biotech Hunter